Cargando…

Cardiovascular Diseases and Marine Oils: A Focus on Omega-3 Polyunsaturated Fatty Acids and Polar Lipids

Cardiovascular diseases (CVD) remain the leading cause of death across the globe, hence, establishing strategies to counteract CVD are imperative to reduce mortality and the burden on health systems. Dietary modification is an effective primary prevention strategy against CVD. Research regarding die...

Descripción completa

Detalles Bibliográficos
Autores principales: Caffrey, Cliodhna, Leamy, Anna, O’Sullivan, Ellen, Zabetakis, Ioannis, Lordan, Ronan, Nasopoulou, Constantina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10672651/
https://www.ncbi.nlm.nih.gov/pubmed/37999373
http://dx.doi.org/10.3390/md21110549
_version_ 1785140441383960576
author Caffrey, Cliodhna
Leamy, Anna
O’Sullivan, Ellen
Zabetakis, Ioannis
Lordan, Ronan
Nasopoulou, Constantina
author_facet Caffrey, Cliodhna
Leamy, Anna
O’Sullivan, Ellen
Zabetakis, Ioannis
Lordan, Ronan
Nasopoulou, Constantina
author_sort Caffrey, Cliodhna
collection PubMed
description Cardiovascular diseases (CVD) remain the leading cause of death across the globe, hence, establishing strategies to counteract CVD are imperative to reduce mortality and the burden on health systems. Dietary modification is an effective primary prevention strategy against CVD. Research regarding dietary supplementation has become increasingly popular. This review focuses on the current in vivo, in vitro, and epidemiological studies associated with that of omega-3 polyunsaturated fatty acids (n-3 PUFAs) and polar lipids (PLs) and how they play a role against CVD. Furthermore, this review focuses on the results of several major clinical trials examining n-3 PUFAs regarding both primary and secondary prevention of CVD. Notably, we place a lens on the REDUCE-IT and STRENGTH trials. Finally, supplementation of PLs has recently been suggested as a potential alternative avenue for the reduction of CVD incidence versus neutral forms of n-3 PUFAs. However, the clinical evidence for this argument is currently rather limited. Therefore, we draw on the current literature to suggest future clinical trials for PL supplementation. We conclude that despite conflicting evidence, future human trials must be completed to confirm whether PL supplementation may be more effective than n-3 PUFA supplementation to reduce cardiovascular risk.
format Online
Article
Text
id pubmed-10672651
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-106726512023-10-24 Cardiovascular Diseases and Marine Oils: A Focus on Omega-3 Polyunsaturated Fatty Acids and Polar Lipids Caffrey, Cliodhna Leamy, Anna O’Sullivan, Ellen Zabetakis, Ioannis Lordan, Ronan Nasopoulou, Constantina Mar Drugs Review Cardiovascular diseases (CVD) remain the leading cause of death across the globe, hence, establishing strategies to counteract CVD are imperative to reduce mortality and the burden on health systems. Dietary modification is an effective primary prevention strategy against CVD. Research regarding dietary supplementation has become increasingly popular. This review focuses on the current in vivo, in vitro, and epidemiological studies associated with that of omega-3 polyunsaturated fatty acids (n-3 PUFAs) and polar lipids (PLs) and how they play a role against CVD. Furthermore, this review focuses on the results of several major clinical trials examining n-3 PUFAs regarding both primary and secondary prevention of CVD. Notably, we place a lens on the REDUCE-IT and STRENGTH trials. Finally, supplementation of PLs has recently been suggested as a potential alternative avenue for the reduction of CVD incidence versus neutral forms of n-3 PUFAs. However, the clinical evidence for this argument is currently rather limited. Therefore, we draw on the current literature to suggest future clinical trials for PL supplementation. We conclude that despite conflicting evidence, future human trials must be completed to confirm whether PL supplementation may be more effective than n-3 PUFA supplementation to reduce cardiovascular risk. MDPI 2023-10-24 /pmc/articles/PMC10672651/ /pubmed/37999373 http://dx.doi.org/10.3390/md21110549 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Caffrey, Cliodhna
Leamy, Anna
O’Sullivan, Ellen
Zabetakis, Ioannis
Lordan, Ronan
Nasopoulou, Constantina
Cardiovascular Diseases and Marine Oils: A Focus on Omega-3 Polyunsaturated Fatty Acids and Polar Lipids
title Cardiovascular Diseases and Marine Oils: A Focus on Omega-3 Polyunsaturated Fatty Acids and Polar Lipids
title_full Cardiovascular Diseases and Marine Oils: A Focus on Omega-3 Polyunsaturated Fatty Acids and Polar Lipids
title_fullStr Cardiovascular Diseases and Marine Oils: A Focus on Omega-3 Polyunsaturated Fatty Acids and Polar Lipids
title_full_unstemmed Cardiovascular Diseases and Marine Oils: A Focus on Omega-3 Polyunsaturated Fatty Acids and Polar Lipids
title_short Cardiovascular Diseases and Marine Oils: A Focus on Omega-3 Polyunsaturated Fatty Acids and Polar Lipids
title_sort cardiovascular diseases and marine oils: a focus on omega-3 polyunsaturated fatty acids and polar lipids
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10672651/
https://www.ncbi.nlm.nih.gov/pubmed/37999373
http://dx.doi.org/10.3390/md21110549
work_keys_str_mv AT caffreycliodhna cardiovasculardiseasesandmarineoilsafocusonomega3polyunsaturatedfattyacidsandpolarlipids
AT leamyanna cardiovasculardiseasesandmarineoilsafocusonomega3polyunsaturatedfattyacidsandpolarlipids
AT osullivanellen cardiovasculardiseasesandmarineoilsafocusonomega3polyunsaturatedfattyacidsandpolarlipids
AT zabetakisioannis cardiovasculardiseasesandmarineoilsafocusonomega3polyunsaturatedfattyacidsandpolarlipids
AT lordanronan cardiovasculardiseasesandmarineoilsafocusonomega3polyunsaturatedfattyacidsandpolarlipids
AT nasopoulouconstantina cardiovasculardiseasesandmarineoilsafocusonomega3polyunsaturatedfattyacidsandpolarlipids